Tyrosinemia Type 1 Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The tyrosinemia type 1 treatment market was valued at USD 67.20 Million in 2025 and is expected to grow at a CAGR of 6.50%, reaching USD 126.14 Million by 2035. Growth is fueled by rising diagnosis rates and adoption of enzyme replacement therapies.

Tyrosinemia Type 1 Treatment Market Overview

Tyrosinemia type 1 is a rare genetic disorder caused by the inability to break down tyrosine, leading to severe liver and kidney complications. The market is driven by advancements in diagnostic technologies and increased awareness. Several market trends such as regulatory approvals and rising demand for innovative therapies impact the market significantly, leading to global market expansion.

Tyrosinemia Type 1 Treatment Market Growth Drivers

Efforts to Enhance Early Diagnosis to Drive the Market Growth

Tyrosinemia type 1, a rare genetic disorder affecting males and females equally, has a global prevalence of approximately 1 in 100,000 to 120,000 births. Increasing awareness and advancements in diagnostic technologies are enabling earlier detection, while the growing demand for innovative treatment options supports market expansion. These factors, combined with improving healthcare infrastructure, are creating significant opportunities for the development and boosting the market value for innovative treatment alternatives.

Tyrosinemia Type 1 Treatment Market Trends

Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows.

Surge in Regulatory Approvals to Augment the Market Demand

The increasing regulatory approvals for drugs reflect a robust growth trajectory in the pharmaceutical industry. For instance, in June 2022, the U.S. FDA approved the abbreviated new drug application for Nitisinone by Analog Pharma and Dipharma S.A. This generic drug is administered to adult and pediatric patients for the treatment of hereditary tyrosinemia type 1 and highlights a favorable environment for generic drug development and commercialization.

Growing Preference for Tablets Anticipated to Drive Tyrosinemia Type 1 Treatment Market Growth

The growing adoption and accessibility of tablets, particularly in developing regions is anticipated to drive the market value in the coming years. For instance, in January 2024, Cycle Pharmaceuticals Ltd and Inceptua Group collaborated to make NITYR (Nitisinone) tablets available through a Free Goods Programme for patients with hereditary tyrosinemia type 1. This initiative provided medicines to developing countries, including India, Bangladesh, and Pakistan, enhancing treatment reach. Such efforts underscore the increasing role of tablet-based therapies in improving patient outcomes and bolstering market growth globally.

Rise in Strategic Mergers and Acquisitions to Meet Rising Tyrosinemia Type 1 Treatment Market Demand

Several market players are stepping forward to enhance their rare disease portfolio. For instance, in October 2023, Eton Pharmaceuticals announced the acquisition of Nitisinone. This FDA-approved ultra-rare disease product was originally developed by Oakrum Pharma, LLC and expanded Eton's tyrosinemia type 1 product portfolio.

Growing Awareness to Boost Tyrosinemia Type 1 Treatment Market Size

Rising awareness around rare diseases such as Tyrosinemia type 1 among healthcare professionals and patients is significantly improving diagnosis rates. This increased awareness is driving the demand for effective treatment options, boosting market growth. As educational initiatives and advocacy campaigns expand globally, the market is anticipated to experience sustained growth in the forecast period.

Tyrosinemia Type 1 Treatment Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug

• Nitisinone
• Others

Market Breakup by Dosage Form

• Tablet
• Capsule
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Tyrosinemia Type 1 Treatment Market Share

Market Share Based on Dosage Form to Witness Substantial Growth

Based on dosage form, the market is divided into tablets, capsules, and others. Among these, the capsule segment is expected to dominate the market share, due to its several advantages such as the ease of swallowing and masking the unpleasant taste and odor of the medications. For instance, in February 2024, Eton Pharmaceuticals officially introduced Nitisinone capsules for the management of tyrosinemia type 1. This medication is distributed through specialized pharmacies and is intended to be used alongside a stringent diet that restricts tyrosine and phenylalanine intake.

Tyrosinemia Type 1 Treatment Market Analysis by Region

Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to account for a substantial market share due to the key market players seeking expedited regulatory approvals to manage the disease effectively. In addition, favorable reimbursement policies and robust healthcare infrastructure further support market growth in the region.

Leading Players in the Tyrosinemia Type 1 Treatment Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Eton Pharmaceuticals

Established in 2017 and headquartered in Deer Park, Illinois, Eton Pharmaceuticals focuses on developing treatments for rare diseases. The company offers ALKINDI SPRINKLE and Betaine Anhydrous, targeting metabolic disorders, including tyrosinemia type 1. Eton is dedicated to improving treatment accessibility for patients with unique therapeutic needs.

Swedish Orphan Biovitrum (Sobi)

Founded in 2001, Sobi is headquartered in Stockholm, Sweden. The company specializes in rare disease therapies and has a focus on innovative solutions for addressing the unmet needs of patients with rare metabolic disorders. Their products include Nitisinone, a key treatment for Tyrosinemia type 1.

Rare Disease Therapeutics (RDT)

Rare Disease Therapeutics, established in 1991 and headquartered in Franklin, Tennessee, focuses on orphan drug development. The company provides Orfadin (Nitisinone) for treating tyrosinemia type 1, ensuring effective care for patients. RDT is committed to advancing treatments for rare and ultra-rare diseases.

Recordati Rare Diseases

Founded in 1926 and headquartered in Milan, Italy, Recordati Rare Diseases develops therapies for rare conditions. The company offers Nitisinone, addressing tyrosinemia type 1. With a strong commitment to innovation, Recordati continues to enhance its portfolio for rare metabolic disorder treatments.

Other companies include WEP Clinical, Torrent Pharma Inc., and Nobelpharma Co., Ltd., among others.

Key Questions Answered in the Tyrosinemia Type 1 Treatment Market

• What was the tyrosinemia type 1 treatment market value in 2025?
• What is the tyrosinemia type 1 treatment market forecast outlook for 2026-2035?
• What are the regional markets covered in The report?
• What is the market segmentation based on the drug?
• What is the market breakup based on the route of dosage form?
• What is the market segmentation based on the distribution channel?
• What are the major factors aiding the tyrosinemia type 1 treatment market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major tyrosinemia type 1 treatment market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the tyrosinemia type 1 treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?